Hims & Hers Health, Inc. has broadened its telehealth portfolio by launching estrogen patch therapy for perimenopause and menopause, with kits priced at $134 per month. The company has secured a steady supply chain to meet the growing demand for hormone replacement therapy, positioning itself to capture a share of the estimated $10 billion+ menopause‑care market.
The move represents a strategic pivot toward broader women’s health services, diversifying revenue beyond the company’s core sexual‑health and weight‑loss categories. By leveraging its existing subscription and fulfillment infrastructure, Hims & Hers aims to capitalize on the rising U.S. demand for hormone therapy, especially after the FDA’s removal of broad “black box” warnings that had previously dampened market growth.
In its Q4 2025 earnings release, Hims & Hers reported revenue of $617.8 million, matching consensus, and an EPS of $0.08, a 92.5% beat over the $0.04 estimate. However, the company guided Q1 2026 revenue at $612.5 million—below the $649 million consensus—raising concerns among investors about future growth. The guidance miss, coupled with competitive pressure from Amazon’s entry into the GLP‑1 market, has tempered enthusiasm for the company’s expansion into menopause care.
Andrew Dudum, co‑founder and CEO, emphasized the company’s growth trajectory, noting that “More than 2.5 million subscribers now rely on us for a healthcare experience that is both accessible and deeply personal – and we believe we’re well on our way to becoming the global leader in consumer health.” Chief Financial Officer Yemi Okupe highlighted the 59% year‑over‑year revenue growth to $2.35 billion in 2025, underscoring the platform’s scalability and the value of new specialty offerings.
The introduction of estrogen patches is expected to strengthen Hims & Hers’ competitive positioning in a market where supply shortages have created opportunities for reliable providers. While the company’s guidance signals caution amid GLP‑1 competition, the new product line is a strategic hedge that could offset margin compression in other segments and support long‑term revenue diversification.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.